Answer extracted from The Conference Room with Simon Lader podcast — listen to the full episode below.
How should early-stage biotech founders build their first product?
Listen deeply to your first and second customer personas to identify the one thing customers care about most, then build a lean product that addresses exactly that—nothing more. Avoid feature bloat and over-engineering before validating core customer needs; the MVP strategy is about focus, not compromise.
The foundation of product strategy for early-stage biotech founders rests on understanding customer urgency. Rather than guessing what features matter, founders must conduct structured conversations with potential customers to uncover their actual pain points. This isn't theoretical market research—it's direct, actionable feedback that shapes every engineering decision.
When Dr. Sherry Zhang built Genopalate, her personalized nutrition company that has since served more than 170,000 customers, she applied this principle rigorously. She focused on what was scientifically sound and commercially viable, avoiding the trap that catches many biotech founders: adding capabilities that sound impressive but don't drive revenue or solve the core problem.
Build a system to prioritize what absolutely matters
Early-stage biotech faces a unique pressure: the science is complex, the regulatory landscape is strict, and founders are often tempted to showcase their technical sophistication. This leads to over-engineering—adding features, running extra studies, or pursuing tangential innovations before the core product has proven its value.
Dr. Zhang emphasizes developing a system to focus on what absolutely matters for revenue generation and nothing else. This means saying no to secondary features, even good ones. It means resisting the urge to perfect every aspect before launch. The MVP strategy for biotech is not about shipping something incomplete; it's about shipping something focused.
As explored in detail in the full episode on Listenly, this discipline requires founders to make difficult choices about scope and trade-offs early on, before capital, team time, and scientific effort are sunk into features customers don't need.
"This drive in me to deliver world-class science and translate that into something useful and practical for everyday people is so strong that I think that will motivate me to learn new skills, to meet new people, to get on stage that I'll be nervous for, and raise funding."
Sherry Zhang — Executive Director of External Strategy and Partnerships at the Price Lab, Buck Institute for Research on Aging, and founder of Genopalate. Dr. Zhang is a first-generation immigrant scientist who arrived in the United States from China with three bags and $3,000. She earned her PhD in molecular biology from Marquette University and conducted obesity genomics research at Medical College of Wisconsin (MCW) under Dr. Ahmed Kaseba, who coined the concept of metabolic syndrome. Her commitment to translating rigorous science into practical solutions has shaped both her founding approach and her ongoing work in longevity and preventive health optimization.
One often-overlooked aspect of MVP strategy in biotech is the founder's own role in execution. Dr. Zhang ran Genopalate while maintaining a full-time faculty position, which forced ruthless prioritization. This constraint, while demanding, also prevented scope creep—a principle she discusses in depth on the podcast, revealing how resource limitation can paradoxically lead to stronger product-market fit.
Key takeaways
- Conduct structured customer conversations with your first and second personas to identify their single most urgent need before building anything.
- Develop a decision-making system that ruthlessly prioritizes revenue-generating features and eliminates everything else—feature creep is the enemy of early-stage validation.
- Avoid over-engineering and secondary innovations until the core MVP has proven traction with real customers.
- Accept that resource constraints (time, capital, team size) can be a powerful forcing function for product focus and faster market validation.
See also
How does leadership differ between academic research, startup founding, and established research institutions?
Scientists are trained to reduce uncertainty through data and hypotheses, while founders must navigate uncertainty as a constant reality. Dr. Zhang combines approaches from both worlds to lead effectively across different contexts.
What are the core mistakes first-time biotech founders make in team building and partnerships?
First-time founders must surround themselves with people who share their dream and align with their principles and values, even if they disagree on specific strategies and approaches.
How should biotech founders approach fundraising and investor relationships?
Trust building and finding aligned investors are critical; rather than accepting funding too quickly, founders should conduct numerous conversations, test compatibility, and prioritize shared vision over capital velocity.